Journal of global antimicrobial resistance最新文献

{"title":"In vitro activity of ceftolozane/tazobactam against Gram-negative bacilli isolated from pediatric patients: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017–2021, China","authors":"","doi":"10.1016/j.jgar.2024.05.017","DOIUrl":"10.1016/j.jgar.2024.05.017","url":null,"abstract":"<div><h3>Objectives</h3><p>Ceftolozane-tazobactam (C/T) is a combination of a cephalosporin and a β-lactamase inhibitor with activity against Gram-negative bacilli (GNB). The study aims were to evaluate the activity of C/T in vitro vs. comparators against clinical GNB isolated from Chinese paediatric patients.</p></div><div><h3>Methods</h3><p>From 2017–2021, 660 GNB isolates were collected from 20 hospitals across China. The minimum inhibitory concentrations were tested using a Trek Diagnostic System (Thermo Fisher Scientific). Susceptibility was determined by CLSI broth microdilution and the results were interpreted according to CLSI M100 (2021) breakpoints.</p></div><div><h3>Results</h3><p>GNB isolates were obtained from paediatric patients &lt; 18 years old, mainly from the bloodstream (<em>n</em> = 146), intraperitoneal cavity (<em>n</em> = 138), lower respiratory (<em>n</em> = 278) and urinary tract (<em>n</em> = 96). Overall, C/T was active against 76.6% of 436 Enterobacterales, with a descending susceptibility rate of 100.0% to <em>S. marcescens</em>, 92.2% to <em>E. coli</em>, 83.3% to <em>K. oxytoca</em>, 66.7% to <em>K. aerogenes</em>, 66.7% to <em>P. mirabilis</em>, 58.6% to <em>K. pneumoniae</em> and 57.1% to <em>E. cloacae</em>. The susceptibility of <em>P. aeruginosa</em> to C/T was 89.4%, which was the highest among the β-lactam antibiotics and was second only to amikacin (92.9%). Isolates of respiratory tract infection (RTI) derived <em>P. aeruginosa</em> were highly susceptible (93.8%) to C/T, while &lt;75% of isolates of RTI derived <em>P. aeruginosa</em> were susceptible to the other β-lactam antibiotics tested, except for ceftazidime-avibactam (91.2%).</p></div><div><h3>Conclusion</h3><p>GNBs collected from paediatric patients in China showed a high susceptibility to C/T making this drug combination an effective choice for treating the paediatric population, especially those infected with <em>P. aeruginosa</em>.</p></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"38 ","pages":"Pages 216-222"},"PeriodicalIF":3.7,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213716524001073/pdfft?md5=a0776fd59d993832166afe2e0e936ff1&pid=1-s2.0-S2213716524001073-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141440571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry","authors":"George Zhanel ,&nbsp;Michael Silverman ,&nbsp;Janhavi Malhotra ,&nbsp;Melanie Baxter ,&nbsp;Reza Rahimi ,&nbsp;Neal Irfan ,&nbsp;Gabriel Girouard ,&nbsp;Rita Dhami ,&nbsp;Melissa Kucey ,&nbsp;Vida Stankus ,&nbsp;Kristin Schmidt ,&nbsp;Sébastien Poulin ,&nbsp;William Connors ,&nbsp;Carlo Tascini ,&nbsp;Andrew Walkty ,&nbsp;James Karlowsky","doi":"10.1016/j.jgar.2024.06.002","DOIUrl":"10.1016/j.jgar.2024.06.002","url":null,"abstract":"<div><h3>Objectives</h3><p>We report the use of IV dalbavancin in Canadian patients using data captured by the national CLEAR registry.</p></div><div><h3>Methods</h3><p>The CLEAR registry uses the web-based data management program, REDCap™ (online survey <span>https://rcsurvey.radyfhs.umanitoba.ca/surveys/?s=TPMWJX98HL</span><svg><path></path></svg>) to facilitate clinicians entering details associated with their clinical experiences using IV dalbavancin.</p></div><div><h3>Results</h3><p>Data were available for 40 patients. The most common infections treated were acute bacterial skin and skin structure infection (ABSSSI) (62.5% of patients), bone/joint infection (22.5%), bloodstream/vascular infection (7.5%) and endocarditis (5.0%). Dalbavancin was used as directed (75.0%) and empiric therapy (25.0%). MRSA was the most common identified pathogen (70.0%). Dalbavancin was used both in outpatient (e.g., emergency department) (65.0%), and inpatient treatment settings (e.g., hospital ward) (35.0%). Dalbavancin was used due to the convenience of a single dose treatment (77.5%) as well as to facilitate hospital discharge (7.5%). Dalbavancin was primarily used alone (90.0%), and most commonly using a single 1500 mg dose (77.5%). Microbiological success (pathogen eradicated or presumed eradicated) occurred in 88.2% of known cases, while clinical success (cure and/or improvement) occurred in 93.3% of known cases. No adverse events were reported.</p></div><div><h3>Conclusions</h3><p>In Canada, IV dalbavancin is used as both directed and empiric therapy to treat ABSSSI as well as off-label (bone/joint, bacteremia/vascular, endocarditis, device-related) infections. It is used in both outpatient and inpatient settings due primarily to its convenience as a single-dose treatment regimen and to facilitate early hospital discharge. Dalbavancin use is associated with high microbiological and clinical cure rates along with an excellent safety profile.</p></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"38 ","pages":"Pages 154-157"},"PeriodicalIF":3.7,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213716524001140/pdfft?md5=5e8b8877e4041899366ae7302986570c&pid=1-s2.0-S2213716524001140-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141440572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fitness cost of tet(A) type I variant-mediated tigecycline resistance in Klebsiella pneumoniae","authors":"Yuanyuan Li ,&nbsp;Tianyu Wang ,&nbsp;Yunbing Li ,&nbsp;Chen Xu ,&nbsp;Tianyi Wang ,&nbsp;Lili Huang ,&nbsp;Xiangkun Zeng ,&nbsp;Guangfen Zhang ,&nbsp;Chunli Li ,&nbsp;Ning Dong","doi":"10.1016/j.jgar.2024.06.003","DOIUrl":"10.1016/j.jgar.2024.06.003","url":null,"abstract":"<div><h3>Objective</h3><p>The aim of the present study is to explore the impact of the <em>tet</em>(A) type I variant (<em>tet</em>A-v1) on its fitness effect in <em>Klebsiella pneumoniae</em>.</p></div><div><h3>Methods</h3><p>Clinical <em>K. pneumoniae</em> strains were utilized as parental strains to generate strains carrying only the plasmid vector (pBBR1MCS-5) or the <em>tet</em>A-v1 recombinant plasmid (p<em>tet</em>A-v1). Antimicrobial susceptibility testing was conducted to estimate the contribution of <em>tet</em>A-v1 to drug resistance. Plasmid stability was evaluated by serial passage over 10 consecutive days in the absence of tigecycline. Biological fitness was examined through growth curve analysis, <em>in vitro</em> competition assays and a neutropenic mouse thigh infection model.</p></div><div><h3>Results</h3><p>A 2–4-fold increase in tigecycline MIC was observed following the acquisition of <em>tet</em>A-v1. Without tigecycline treatment, the stability of p<em>tet</em>A-v1 plasmids has been decreasing since day 1. The p<em>tet</em>A-v1 plasmid in Kp89, Kp91, and Kp93 exhibited a decrease of about 20% compared to the pBBR1MCS-5 plasmid. The acquisition of the <em>tet</em>A-v1 gene could inhibit the growth ability of <em>K. pneumoniae</em> strains both <em>in vitro</em> and <em>in vivo. tet</em>A-v1 gene imposed a fitness cost in <em>K. pneumoniae</em>, particularly in the CRKP strain Kp51, with a W value of approximately 0.56.</p></div><div><h3>Conclusion</h3><p>The presence of <em>tet</em>A-v1 is associated with a significant fitness cost in <em>K. pneumoniae</em> in the absence of tigecycline, both <em>in vitro</em> and <em>in vivo</em>.</p></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"38 ","pages":"Pages 158-162"},"PeriodicalIF":3.7,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213716524001127/pdfft?md5=9704661f616749c4b4ac6f959c89237e&pid=1-s2.0-S2213716524001127-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141327523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic characterization and resistance features of Streptococcus agalactiae isolated from non-pregnant adults in Shandong, China","authors":"Xinyi Gong ,&nbsp;Yan Jin ,&nbsp;Xiao Han ,&nbsp;Xueqi Jiang ,&nbsp;Beibei Miao ,&nbsp;Shuang Meng ,&nbsp;Jingyi Zhang ,&nbsp;Haijian Zhou ,&nbsp;Han Zheng ,&nbsp;Jie Feng ,&nbsp;Juan Li","doi":"10.1016/j.jgar.2024.06.001","DOIUrl":"10.1016/j.jgar.2024.06.001","url":null,"abstract":"<div><h3>Background</h3><p><em>Streptococcus agalactiae</em> is a recognized pathogen that primarily affects infants and pregnant women. However, its increasingly important role in causing invasive infections among non-pregnant adults has become a significant health concern due to the severity and variety of its clinical impacts.</p></div><div><h3>Methods</h3><p>Nonduplicate <em>S. agalactiae</em> clinical strains associated with clinical infections (<em>n</em> = 139) were isolated from non-pregnant adults in Shandong, China. Antibiotic susceptibility testing, whole-genome sequencing and genomic analyses were conducted to characterize the genome and identify resistance features of these strains.</p></div><div><h3>Results</h3><p>The strains exhibited universal susceptibility to penicillin, ampicillin, cefotaxime, meropenem, linezolid and vancomycin. Notably, high resistance rates were observed for erythromycin (91.4%), clindamycin (89.2%), levofloxacin (84.2%), tetracycline (54.0%) and, to a lesser extent, chloramphenicol (12.9%). Serotyping revealed seven serotypes and one non-typeable strain. Serotypes Ia, Ib, III and V predominated, representing 95.7% of the strains. Nineteen sequence types were categorized into seven clonal complexes, with CC10 being the most prevalent at 48.9%. The resistance genes <em>mre</em>A (100%), <em>erm</em>B (70.5%) and <em>tet</em>M (46.0%) were commonly detected. All the isolates carried at least one pilus backbone determinant and one alpha-like protein gene, with the PI-1+PI-2a and the <em>bca</em> gene being the most frequent at 84.2% and 54.7%, respectively.</p></div><div><h3>Conclusions</h3><p>While <em>S. agalactiae</em> strains in non-pregnant adults retain sensitivity to β-lactam antibiotics, the elevated resistance to erythromycin, clindamycin, levofloxacin and tetracycline is concerning. Given the growing elderly population worldwide, the burden of <em>S. agalactiae</em> infections is significant. Continuous surveillance of serotype distribution and antibiotic resistance patterns is imperative for targeted prevention and therapeutic strategies.</p></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"38 ","pages":"Pages 146-153"},"PeriodicalIF":3.7,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213716524001115/pdfft?md5=807d63277c021014341fc48520a1ef17&pid=1-s2.0-S2213716524001115-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141310836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unravelling the genomic characteristics of a Klebsiella quasipneumoniae clinical isolate carrying blaNDM-1","authors":"","doi":"10.1016/j.jgar.2024.05.022","DOIUrl":"10.1016/j.jgar.2024.05.022","url":null,"abstract":"<div><h3>Objective</h3><p>Despite the increasing reports of <em>bla</em>_NDM in <em>Enterobacterales</em> in Brazil, comprehensive whole genome sequencing (WGS) data remain scarce. To address this knowledge gap, our study focuses on the characterization of the genome of an New Delhi Metallo-β-lactamase (NDM)-1-producing <em>Klebsiella quasipneumoniae</em> subsp. <em>quasipneumoniae</em> (KQPN) clinical strain isolated in Brazil.</p></div><div><h3>Methods</h3><p>The antimicrobial susceptibility profile of the A-73.113 strain was performed by agar dilution or broth microdilution following the Brazilian Antimicrobial Susceptibility Testing Committee/European Committee on Antimicrobial Susceptibility Testing recommendations. WGS was performed using the Illumina® NextSeq platform and the generated reads were assembled using the SPAdes software. The sequences obtained were submitted to the bioinformatics pipelines to determine the sequence type, resistome, plasmidome, and virulome.</p></div><div><h3>Results</h3><p>The A-73.113 strain was identified as KQPN and was susceptible to polymyxins (MICs, ≤0.25 µg/mL), tigecycline (MIC, 0.5 µg/mL), ciprofloxacin (MIC, 0.5 µg/mL), and levofloxacin (MIC, 1 µg/mL). WGS analysis revealed the presence of genes conferring resistance to β-lactams (<em>bla</em>_NDM-1, <em>bla</em>_CTX-M-15, <em>bla</em>_OXA-9, <em>bla</em>_OKP-A-5, <em>bla</em>_TEM-1), aminoglycosides [<em>aph(3′)-VI, aadA1, aac(6′)-Ib</em>], and fluoroquinolones (<em>oqxAB, qnrS1, aac(6′)-Ib-cr</em>]. Additionally, the presence of the plasmid replicons Col(pHAD28), IncFIA(HI1), IncFIB(K) (pCAV1099-114), IncFIB(pQil), and IncFII(K), as well as virulence-encoding genes <em>fimABCDEFGHIK</em> (type 1 fimbria), <em>pilW</em> (type IV pili), <em>iutA</em> (aerobactin), <em>entABCDEFS</em>/<em>fepABCDG</em>/<em>fes</em> (Ent siderophores), <em>iroE</em> (salmochelin), and <em>allABCDRS</em> (allantoin utilization) was verified. Furthermore, we found that the A-73.113 strain belongs to ST1040.</p></div><div><h3>Conclusions</h3><p>Here we report the genomic characteristics of an NDM-1-producing KQPN ST1040 strain isolated from blood cultures in Brazil. These data will enhance our comprehension of how this species contributes to the acquisition and dissemination of <em>bla</em>_NDM-1 in Brazilian nosocomial settings.</p></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"38 ","pages":"Pages 302-305"},"PeriodicalIF":3.7,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213716524001103/pdfft?md5=12cf0fac85f82b861c677a2563aeface&pid=1-s2.0-S2213716524001103-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141296159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of the Rapid Emergence of Colistin Resistance in a Newborn Infected with KPC-2–Producing Hypervirulent Carbapenem-Resistant Klebsiella pneumoniae","authors":"","doi":"10.1016/j.jgar.2024.05.021","DOIUrl":"10.1016/j.jgar.2024.05.021","url":null,"abstract":"<div><h3>Objectives</h3><p>Hypervirulent carbapenem-resistant <em>Klebsiella pneumoniae</em> (hv-CRKp) poses a significant threat to public health. This study reports an infection related to hv-CRKp in a premature infant and reveals its colistin resistance and evolutionary mechanisms within the host.</p></div><div><h3>Methods</h3><p>Three KPC-producing CRKp strains were isolated from a patient with sepsis and CRKp osteoarthritis who had been receiving colistin antimicrobial therapy. The minimum inhibitory concentrations (MICs) of ceftazidime, ceftazidime-avibactam (CAZ-AVI), meropenem, imipenem, tigecycline, amikacin, minocycline, sulfamethoxazole/trimethoprim, ciprofloxacin, levofloxacin, aztreonam, cefepime, cefoperazone/sulbactam, piperacillin/tazobactam, and colistin were determined using the microbroth dilution method. The whole-genome sequencing analysis was conducted to determine the sequence types (STs), virulence genes, and antibiotic resistance genes of the three CRKp strains.</p></div><div><h3>Results</h3><p>Whole-genome sequencing revealed that all three CRKp strains belonged to the ST11 clone and carried a plasmid encoding <em>blaKPC-2</em>. The three strains all possessed the <em>iucABCDiutA</em> virulence cluster, <em>peg-344</em> gene, and <em>rmpA/rmpA2</em> genes, defining them as hv-CRKp. Further experiments and whole-genome analysis revealed that a strain of <em>K. pneuomniae</em> had developed resistance to colistin. The mechanism found to be responsible for colistin resistance was a deletion mutation of approximately 9000 bp including the <em>mgrB</em> gene.</p></div><div><h3>Conclusion</h3><p>This study characterizes colistin resistance of the ST11 clone hv-CRKp during colistin treatment and its rapid evolution within the host.</p></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"38 ","pages":"Pages 265-270"},"PeriodicalIF":3.7,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213716524001097/pdfft?md5=3c9c0bc13fd2c7866f768758e08cac0b&pid=1-s2.0-S2213716524001097-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141288194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic and Phylogenomic Characterization of Carbapenem-resistant Pseudomonas aeruginosa ‘High-risk’ Clone O4/ExoS+/ST654 Circulating in Chilean Hospitals","authors":"","doi":"10.1016/j.jgar.2024.05.015","DOIUrl":"10.1016/j.jgar.2024.05.015","url":null,"abstract":"<div><h3>Introduction</h3><p>Carbapenem-resistant <em>Pseudomonas aeruginosa</em> (CRPA) is a serious threat to public health. Globally, carbapenemases-producing CRPA isolates mainly belong to ‘high-risk’ clones; however, the molecular epidemiology of CRPA isolates circulating in Chile are scarce, where this pathogen is the main aetiological agent of ventilator-associated pneumonia.</p></div><div><h3>Objectives</h3><p>To characterize the phylogenomics and molecular features of ST654 CRPA isolates collected in Chile between 2016 and 2022.</p></div><div><h3>Methods</h3><p>Eighty-nine CRPA isolates collected in different Chilean hospitals from clinical specimens between 2005 and 2022 were analysed. Antibiotic susceptibility tests and carbapenemases production were carried out on the CRPA ST654 isolates. Also, they were subjected to whole-genome sequencing, from which in silico analyses were performed.</p></div><div><h3>Results</h3><p>Thirty-four strains (38.2%) belonged to the ST654 high-risk clone, being the most predominant lineage of the collection. Most of these isolates belonged to a subclade including KPC producers that also clustered with strains from Argentina and the United States, whereas few VIM and NDM co-producers clustered in two different smaller subclades. The isolates exhibited a broad resistome encompassing genes mediating resistance to several other clinically relevant drugs. Additionally, all the 34 ST654 isolates were ExoS+ as a virulence factor and associated to the O4-serotype.</p></div><div><h3>Conclusions</h3><p>Our report represents the most comprehensive phylogenomic study of a CRPA high-risk clone ST654 to date. Our analyses suggest that this lineage is undergoing a divergent evolutionary path in Chile, because most of the isolates were KPC producers and were O4 serotype, differing from previous descriptions, which underline the relevance of performing molecular surveillance on this pathogen.</p></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"38 ","pages":"Pages 205-211"},"PeriodicalIF":3.7,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213716524001036/pdfft?md5=4e9de80b0f2d33d69667ef43d780bc70&pid=1-s2.0-S2213716524001036-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141288193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint","authors":"Julien Massol ,&nbsp;Aurélien Dinh ,&nbsp;Katy Jeannot ,&nbsp;Clara Duran ,&nbsp;Frédérique Bouchand ,&nbsp;Anaïs Potron ,&nbsp;Laurent Dortet ,&nbsp;François Jehl","doi":"10.1016/j.jgar.2024.05.014","DOIUrl":"10.1016/j.jgar.2024.05.014","url":null,"abstract":"<div><h3>Objectives</h3><p><em>Acinetobacter baumannii</em> is classified by the centre for Disease Control and Prevention (CDC) as an \"urgent threat\" due to its ability to acquire and develop resistance to multiple classes of antibiotics. As a result, it is one of the most concerning pathogens in healthcare settings, with increasing incidence of infections due to carbapenem-resistant <em>Acinetobacter baumannii</em> (CRAB) associated with high morbidity and mortality rates. Therefore, there are ongoing efforts to find novel treatment options, one of which is cefiderocol. We aim to review available evidence on cefiderocol use for severe nosocomial pneumonia due to carbapenem-resistant <em>Acinetobacter baumannii.</em></p></div><div><h3>Methods</h3><p>A comprehensive review was conducted from 2017 to 2023, covering articles from databases such as Pubmed, Scopus, and Embase, along with conference proceedings from ECCMID 2023. The primary focus was on severe nosocomial pneumonia due <em>A. baumannii</em> and cefiderocol.</p></div><div><h3>Discussion</h3><p>Cefiderocol, targeting periplasmic space Penicillin-Binding Proteins (PBPs) via siderophore transport pathways, exhibits promise against multi-drug resistant Gram-negative bacilli. Its effectiveness in treating CRAB pneumonia remains debated. The CREDIBLE trial reported higher mortality with cefiderocol compared to the best available treatment, while other cohort studies showed contrasting outcomes. Patient variations and pharmacokinetic factors may underlie these discrepancies. The recommended cefiderocol dosage regimen may fall short of desired pharmacokinetic targets, especially in critically ill patients and lung infections. Pulmonary factors hindering cefiderocol's entry into bacteria through iron transporters are overlooked in clinical breakpoints. Optimized dosing or combination regimens may enhance infection site exposure and outcomes.</p></div><div><h3>Conclusions</h3><p>Further research is needed to determine the optimal cefiderocol dosage and administration (mono vs. dual therapy, continuous vs. intermittent infusion), in severe <em>Acinetobacter baumannii</em> nosocomial pneumonia.</p></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"38 ","pages":"Pages 140-145"},"PeriodicalIF":3.7,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213716524001024/pdfft?md5=c2bf8f7a34c11d56e445ecce8e27fbac&pid=1-s2.0-S2213716524001024-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141283883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “The fexA gene in Campylobacter: whether the spread has occurred among various hosts in eastern China” [Journal of Global Antimicrobial Resistance 36 (2024) 293-300]","authors":"Pingyu Huang ,&nbsp;Chong Chen ,&nbsp;Xiaoqi Zang ,&nbsp;Qinyue Jiang ,&nbsp;Yilin Lv ,&nbsp;Hongyue Lv ,&nbsp;Yanying Qin ,&nbsp;Xinan Jiao ,&nbsp;Jinlin Huang","doi":"10.1016/j.jgar.2024.03.001","DOIUrl":"10.1016/j.jgar.2024.03.001","url":null,"abstract":"","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"37 ","pages":"Page 245"},"PeriodicalIF":4.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213716524000523/pdfft?md5=c16f3cbed68d904f5fb8e0172116eb9a&pid=1-s2.0-S2213716524000523-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140149731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Letter in response to first case of persistent Stenotrophomonas maltophilia bacteremia due to septic thrombosis successfully treated with a Cefiderocol-containing regimen” [Journal of Global Antimicrobial Resistance 36 (2024) 307-308]","authors":"Gayatree Nayak,&nbsp;Sushree Sarathi,&nbsp;Bijayini Behera,&nbsp;Ashoka Mahapatra,&nbsp;Jayanti Jena,&nbsp;Srujana Mohanty","doi":"10.1016/j.jgar.2024.02.020","DOIUrl":"10.1016/j.jgar.2024.02.020","url":null,"abstract":"","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"37 ","pages":"Page 244"},"PeriodicalIF":4.6,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213716524000481/pdfft?md5=de107c57c926f6cc30a0e764a9b59d7a&pid=1-s2.0-S2213716524000481-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140154151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}